Sign In
Buy BNTC
$11.71
-0.150 (-1.26%)
At Close: Jul 31, 2026
-Subject 1 and Subject 2 experienced durable, clinically meaningful improvements in swallowing at 9-months and 6-months post-BB-301 treatment, respectively, with Subject 2 achieving a Sydney Swallow Q
Benitec Biopharma Releases Full Year 2024 Financial Results and Provides Operational Update
04:30pm, Thursday, 26'th Sep 2024
-Positive 90-day and 180-day Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with the Low-Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study R
HAYWARD, Calif., Sept. 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing
-The post-dose average values for Total Pharyngeal Residue (i.e., the amount of solid food or liquid material remaining in the pharynx after the first swallow) remained meaningfully reduced at the 180
Benitec Biopharma Releases Third Quarter 2024 Financial Results and Provides Operational Update
08:15am, Monday, 13'th May 2024
-Positive Interim Clinical Trial Data for the First Oculopharyngeal Muscular Dystrophy (OPMD) Subject Dosed with BB-301 in the Phase 1b/2a Clinical Treatment Study Reported in April-
Benitec Biopharma Reports Positive Interim Clinical Trial Data for First OPMD Subject Treated with BB-301 in Phase 1b/2a Study
07:30am, Thursday, 18'th Apr 2024
-First efficacy signals demonstrated for a gene therapy under development for Oculopharyngeal Muscular Dystrophy (OPMD) which affects ~15,000 patients worldwide-
Benitec Biopharma Announces Oversubscribed Private Placement Financing of $40.0 Million
07:00am, Thursday, 18'th Apr 2024
HAYWARD, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing
Benitec Biopharma Releases Second Quarter 2024 Financial Results and Provides Operational Update
08:00am, Tuesday, 13'th Feb 2024
-First Subject Dosed with BB-301 in Phase 1b/2a Clinical Treatment Study (NCT06185673) in November 2023- -Data Safety Monitoring Board Review for First Subject Completed After Day 28 Study Visit- -Sec
Announcement marks the initiation of the first clinical trial conducted in human subjects employing Benitec's “Silence and Replace” DNA-directed RNA interference gene therapy platform Announcement
Benitec Biopharma to Participate in a Fireside Chat at the 35th Annual Piper Sandler Healthcare Conference
08:00am, Friday, 17'th Nov 2023
HAYWARD, Calif., Nov. 17, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing nove
Benitec Biopharma Releases First Quarter 2024 Financial Results and Provides Operational Update
08:00am, Monday, 13'th Nov 2023
HAYWARD, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing nove
Benitec Biopharma Releases Full Year 2023 Financial Results and Provides Operational Update
08:00am, Thursday, 21'st Sep 2023
Received FDA Clearance of the Investigational New Drug (IND) application for BB-301 for the Treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-Related Dysphagia
Benitec Biopharma Inc. Announces Closing of $30 Million Underwritten Public Offering
01:00pm, Friday, 11'th Aug 2023
HAYWARD, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing
Benitec Biopharma Inc. Announces Pricing of $30 Million Underwritten Public Offering
10:30pm, Tuesday, 08'th Aug 2023
HAYWARD, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing
Benitec Biopharma Announces 1-for-17 Reverse Stock Split Effective July 26, 2023
01:00pm, Tuesday, 25'th Jul 2023
HAYWARD, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing nove
